Evidence item

The result comes from an open-label single-arm phase 1b/2 study at 12 South Korean centers in HER2-positive advanced biliary cancer. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15122

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:842409089f634b17f996dd55c93130db6827a2f2acba69ba897c21af2d34d5e2

The HERBOT study was an open-label, single-arm, phase 1b/2 trial performed at 12 academic cancer centers in South Korea to evaluate the efficacy and safety of a quadruplet regimen ... as first-line therapy for HER2-positive unresectable advanced BTC.